Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug

Japanese Journal of Pharmacology

Volumn 88, Issue 4, 2002, Pages 379-397

  Ohmori, Kenji ^a   Hayashi, Ken Ichi ^a   Kaise, Toshihiko ^a   Ohshima, Etsuo ^a   Kobayashi, Satoshi ^a   Yamazaki, Takashi ^a   Mukouyama, Akimichi ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

Allergic rhinoconjunctivitis; Chronic urticaria; Cutaneous diseases with pruritus; Olopatadine

Indexed keywords

2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; ANTIALLERGIC AGENT; ANTIFUNGAL AGENT; ASTEMIZOLE; AUTACOID; AZELASTINE; CALCIMYCIN; CALCITONIN GENE RELATED PEPTIDE; CETIRIZINE; CLEMASTINE; CROMOGLYCATE DISODIUM; EBASTINE; EPINASTINE; HISTAMINE H1 RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; ITRACONAZOLE; KETOTIFEN; LANEPITANT; LEUKOTRIENE; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROKININ 2 RECEPTOR ANTAGONIST; OLOPATADINE; OXATOMIDE; PHOSPHORAMIDON; RAMATROBAN; SAREDUTANT; TACHYKININ; TERFENADINE; THROMBOXANE; UNINDEXED DRUG; DIBENZOXEPIN DERIVATIVE; EYE DROPS;

ALLERGIC CONJUNCTIVITIS; ALLERGIC RHINITIS; ASTHMA; CHRONIC URTICARIA; CLINICAL TRIAL; DERMATITIS; DISEASE MODEL; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INDICATION; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG STRUCTURE; ECZEMA; EOSINOPHIL; ERYTHEMA MULTIFORME; GUINEA PIG; HEART ARRHYTHMIA; HEART MUSCLE CELL; HUMAN; INHIBITION KINETICS; LEUKOCYTE FUNCTION; MUSCLE ACTION POTENTIAL; NONHUMAN; POLYMORPHONUCLEAR CELL; PRURIGO; PRURITUS; PSORIASIS VULGARIS; REVIEW; RHINOCONJUNCTIVITIS; SKIN ALLERGY; SKIN DISEASE; SYMPTOMATOLOGY; URINARY EXCRETION; ANIMAL; DRUG ADMINISTRATION ROUTE; DRUG ANTAGONISM; HYPERSENSITIVITY; METABOLISM; PERENNIAL RHINITIS; URTICARIA;

ANIMALS; ANTI-ALLERGIC AGENTS; ASTHMA; CLINICAL TRIALS; CONJUNCTIVITIS, ALLERGIC; DIBENZOXEPINS; DRUG ADMINISTRATION ROUTES; HISTAMINE H1 ANTAGONISTS; HUMANS; HYPERSENSITIVITY; INFLAMMATION MEDIATORS; OPHTHALMIC SOLUTIONS; PRURITUS; RHINITIS, ALLERGIC, PERENNIAL; URTICARIA;

EID: 0035985268     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.88.379     Document Type: Review

References (111)

1. Synthesis and antiallergic activity of 11-(aminoalkylidene)-6,11-dihydrodibenz[b,e]oxepin derivatives
2. Pharmacological studies on KW-4679, an antiallergic drug (1): Inhibitory effect on passive cutaneous anaphylaxis (PCA) and experimental asthma in rats and guinea pigs
3. Pharmacological studies on KW-4679, an antiallergic drug - Inhibitory effect on passive cutaneous anaphylaxis (PCA) and bronchoconstriction in rats and guinea pigs
4. The effect of KW-4679, an antiallergic drug, on experimental allergic rhinitis
5. Effect of (Z)-11-[3-(dimethylamino)propyllidene]-6,11-dihydrobenz[b,e]oxepin-2-acetic acid hydrochloride on experimental allergic conjunctivitis and rhinitis in rats and guinea pigs
6. Mediators of nasal blockage in allergic rhinitis
7. Accuracy of measurement of acoustic rhinometry applied to small experimental animals
8. The effect of KW-4679, an antiallergic drug, on experimental allergic rhinitis in guinea pigs: Effects on nasal blockage
9. Biochemical properties of eosinophils and their preferential accumulation mechanism in nasal allergy
10. Inhibitory effect of KW-4679 on the infiltration of eosinophils in the nasal mucosa of rat allergic rhinitis models
11. Effects of oxatomide and KW-4679 on acetylcholine-induced responses in the isolated acini of guinea pig glands
12. Effects of KW-4679, a new orally active antiallergic drug, on antigen-induced bronchial hyperresponsiveness, airway inflammation and immediate and late asthmatic responses in guinea pigs
13. Effect of KW-4679, an orally active antiallergic drug, on antigen-induced airway hyperresponsiveness in actively sensitized guinea pigs
14. Control of respiratory frequency
15. Histamine produced by macrophage and T lymphocyte: A new type of signal transducer
16. Analysis of histamine-producing cells at the late phase of allergic inflammation in rats
17. 1 receptor
18. 1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis
19. 194
20. 1 receptor
21. The antihistaminic effect of KW-4679, a novel antiallergic drug
22. Leukocyte interactions with vascular endothelium. New insights into selectin-mediated attachment and rolling
23. Histamine enhanced the TNF-α-induced expression of E-selectin and ICAM-1 on vascular endothelial cells
24. Histamine activates bronchial epithelial cells to release inflammatory cytokines in vitro
25. Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs
26. Role of eicosanoids in PAF-induced increases of the vascular permeability in rat airway
27. Leukotrienes: Mediators of immediate hypersensitivity reaction and inflammation
28. Effect of KW-4679, an novel antiallergic drug, on histamine and leukotriene release from rat peritoneal exudates cells
29. Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells
30. KW-4679, an antiallergic drug, inhibits the production of inflammatory lipids in human polymorphonuclear leukocytes and guinea pig eosinophiles
31. Inhibitory effect of olopatadine hydrochloride (KW-4679), a novel antiallergic drug, on peptide leukotriene release from human eosinophiles
32. Effect of olopatadine hydrochloride on the increase of histamine and peptide-leukotrienes concentrations in nasal lavage fluid following the antigen-antibody reaction in actively sensitized guinea pigs
33. 2 and histamine from nasal mucosa after antigen-antibody reaction in guinea pigs
34. Comparative role of peptide leukotrienes and histamine in the development of nasal mucosal swelling in nasal allergy
35. 2 receptor antagonist, on nasal cavity volume and minimum cross-sectional area and nasal mucosal hemodynamics after nasal mucosal allergen challenge in patients with perennial allergic rhinitis
36. Coexistence of multiple peptide and classical transmitters in airway neurons: Functional and pathophysiologic aspects
37. New concepts in the pathogenesis of bronchial hyperresponsiveness and asthma
38. Damage of the airway epithelium and bronchial reactivity in patients with asthma
39. Involvement of neurogenic inflammation in antigen-induced bronchoconstriction in guinea pig
40. Pharmacological characterization of the guinea pig tracheo-bronchial smooth muscle
41. KW-4679-induced inhibition of tachykininergic contraction in the guinea-pig bronchi by prejunctional inhibition of peripheral sensory nerve
42. 2) receptor
43. Inhibitory effect of KW-4679, an anti-allergic drug, on tachykinin-mediated airway response induced by electrical vagal stimulation in guinea pigs
44. Substance P and neurokinin A in human nasal mucosa
45. Expression of NPY Y1 and CGRP receptors in human nasal mucosa: Implications in allergic rhinitis
46. Clinical and inflammatory responses to exogeneous tachykinins in allergic rhinitis
47. Mediation of prolonged increases in nasal mucosal blood flow by calcitonin gene-related peptide (CGRP)
48. Role of substance P in the vascular response of nasal mucosa in nasal allergy
49. Involvement of neuropeptides in the allergic nasal obstruction in guinea pigs
50. Pharmacological characterization of LY303870: A novel, potent and selective nonpeptide substance P (neurokinin-1) receptor antagonist
51. Comparative affinities and antagonistic potencies of various human calcitonin gene-related peptide receptors in brain and periphery
52. Inhibitory effect of olopatadine hydrochloride on the sneezing response induced by intranasal capsaicin challenge in guinea pigs
53. Local and systemic capsaicin pretreatment inhibits sneezing and the increase in nasal permeability induced by certain chemical irritants
54. Substance P as a potent stimulator of sneeze responses in experimental allergic rhinitis of guinea pigs
55. Effects of topical capsaicin on autonomic nerves in experimentally-induced nasal hypersensitivity. An immunocytochemical study
56. Secretion, pain and sneezing induced by the application of capsaicin to the nasal mucosa in man
57. 1) in the trigeminal dorsal horn
58. Localization of eosinophil granule major basic protein in chronic urticaria
59. Immunohistological comparison of granulated cell proteins in immediate urticarial dermographism and delayed pressure urticaria lesions
60. Production of wheal-and-flare skin reactions by eosinophil granule proteins
61. Biochemical and amino acid sequence analysis of human eosinophil granule major basic protein
62. Cationic proteins induce airway hyperresponsiveness dependent on charge interactions
63. The effect of human eosinophil granule major basic protein on airway responsiveness in the rat in vivo. A comparison with polycations
64. The effect of polyamino acids on the blood vessels of the rat
65. Structure-activity relationships for some substance P-related peptides that cause wheal and flare reactions in human skin
66. Differential release of histamine and eicosanoids from human skin mast cells activated by IgE-dependent and non-immunological stimuli
67. Activated eosinophils elicit substance P release from cultured dorsal root ganglion neurons
68. Roles of mast cells and sensory nerves in cutaneous vascular hyperpermeability and scratching behavior induced by poly-L-arginine in rats
69. Effects of olopatadine hydrochloride on the cutaneous vascular hyperpermeability and scratching behavior induced by poly-L-arginine in rat
70. General pharmacology of KW-4679, an antiallergic drug (1st report) - Effects on central nervous system, autonomic nervous system and peripheral nervous system
71. General pharmacology of KW-4679, an antiallergic drug (2nd report) - Effects on respiratory and circulatory system, urogenital system and digestive system
72. A single dose toxicity study of KW-4679 in mice, rats and dogs
73. Toxicity studies of KW-4679 - A 13-week repeated dose toxicity study in rats
74. Toxicity studies of KW-4679 - A 52 week repeated dose toxicity study in dogs
75. Reproductive and developmental toxicity study of KW-4679 - Fertility study in rats
76. Reproductive and developmental toxicity study of KW-4679 - Teratogenicity study in rat
77. Reproductive and developmental study of KW-4679 - Teratogenecity study in rabbits
78. Drug-induced torsades de pointes: From molecular biology to bedside
79. Effect of terfenadine and KW-4679, a novel antiallergic compound, on action potential of guinea pig ventricular myocytes
80. Inhibitory effects of terfenadine on the rising phase of action potentials and sinus rates in isolated guinea-pig myocardium
81. Itraconazole prevents terfenadine metabolism and increase risk of torsades de pointes ventricular tachycardia
82. Effect of olopatadine hydrochloride, a novel antiallergic agent, on the QT interval
83. Phase I clinical study on KW-4679, an antiallergic drug - Safety and pharmacokinetics in the single and repeated administration, study to healthy subjects
84. Determination of olopatadine, a new antiallergic agent, and its metabolites in human plasma by high-performance liquid chromatography with electrospray ionization tandem mass spectrometry
85. Pharmacokinetics of KW-4679 in the elderly: Single-dose and multiple-dose trials
86. Pharmacokinetics of KW-4679 in patients with renal insufficiency
87. Disposition of KW-4679 (6): Pharmacokinetics in experimental animals
88. 14C-KW-4679 after oral or intravenous administration to rats
89. 14C-KW-4679 after oral administration to dogs
90. 14C-epinastine hydrochloride (WAL 801 C1) (I). Blood level, tissue distribution and urinary and fecal excretion after single and repeated administration in rats
91. The biological fate of 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)benzimidazole difumarate (KB-2413). II. Distribution after single and multiple oral administration to rats
92. Metabolic disposition of terfenadine in laboratory animals
93. 14C-KW-4679 to fetus and milk after oral administration to rats
94. Disposition of KW-4679 (4): Metabolism of KW-4679 in rats and dogs
95. 14C-KW-4679 after multiple oral administrations in rats and effect of KW-4679 on drug metabolizing enzyme in rats
96. Comparison of a new antihistaminic and antiallergic compound KW4679 with terfenadine and placebo on skin and nasal provocation in atopic individuals
97. Early phase II study of KW-4679 (olopatadine hydrochloride) on chronic urticaria
98. Late phase II study of KW-4679 (olopatadine hydrochloride) on chronic urticaria - Optimal dose finding study by double blind technique
99. Phase III study of KW-4679 (olopatadine hydrochloride) on chronic urticaria - A double blind study in comparison with ketotifen fumarate
100. Long-term treatment of KW-4679 (olopatadine hydrochloride) on chronic urticaria
101. Clinical study of KW-4679 (olopatadine hydrochloride) on pruritic diseases
102. Safety and efficacy of KW-4679 (olopatadine hydrochloride) tablets in bronchial asthma - Early phase II study
103. Late phase II study for optimal dose finding of KW-4679 (olopatadine hydrochloride) tablets in bronchial asthma - Multi-center double-blind study compared with placebo control
104. Usefulness of KW-4679 (olopatadine hydrochloride) tablets in bronchial asthma - Multicenter double-blind study compared with terfenadine
105. A long-term administration study of KW-4679 (olopatadine hydrochloride) tablets on bronchial asthma
106. Long-term use experience of KW-4679 (olopatadine hydrochloride) tablets in bronchial asthma
107. The current and future therapy of allergic conjunctivitis
108. Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using conjunctival allergen challenge
109. Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model
110. Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptoms
111. The added benefit of local patanol therapy when combined with systemic claritin for the inhibition of ocular itching in the conjunctival antigen challenge model